Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Sutro Biopharma Stock Performance
Shares of STRO Stock traded down $0.04 during mid-day trading on Thursday, hitting $6.60. The stock had a trading volume of 4,147 shares, compared to its average volume of 471,550. Sutro Biopharma has a fifty-two week low of $3.33 and a fifty-two week high of $23.70. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.44 and a quick ratio of 7.44. The company's 50-day simple moving average is $5.46 and its 200-day simple moving average is $6.69. The firm has a market cap of $344.26 million, a PE ratio of -2.27 and a beta of 0.94.
Sutro Biopharma (NASDAQ:STRO - Get Rating) last posted its earnings results on Monday, August 8th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.09). Sutro Biopharma had a negative return on equity of 55.57% and a negative net margin of 252.33%. Sell-side analysts anticipate that Sutro Biopharma will post -2.36 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have commented on STRO. Piper Sandler increased their price objective on shares of Sutro Biopharma to $16.00 in a research report on Monday, July 4th. Wells Fargo & Company reiterated an "overweight" rating and set a $15.00 target price on shares of Sutro Biopharma in a research report on Thursday. JMP Securities reissued a "buy" rating and issued a $20.00 target price on shares of Sutro Biopharma in a research report on Wednesday, July 6th. HC Wainwright cut their price target on Sutro Biopharma from $35.00 to $30.00 in a research report on Wednesday, May 11th. Finally, Wedbush decreased their price objective on Sutro Biopharma from $30.00 to $20.00 in a report on Tuesday, May 10th.